Archive · 2 Jul 2025
Aurobindo Pharma Arm Receives EU Approval for Cancer Drug
Imagine a company made a copy of a medicine called Dazublys, which is used to fight certain types of cancer.
A part of Aurobindo Pharma, called CuraTeQ Biologics, got the okay from Europe to sell this medicine.
This medicine helps treat cancers that have a special marker called HER2.
This means the medicine can be used in Europe.
The company's stock also went up in value because of this good news.
CuraTeQ Biologics, an Aurobindo Pharma unit, received EU approval for Dazublys.
Dazublys is a trastuzumab biosimilar drug.
The drug is for treating HER2-positive breast and gastric cancers.
Aurobindo Pharma's shares increased by 2.23% on the BSE.
The approval comes from the European Commission.
- Who
- CuraTeQ Biologics, an Aurobindo Pharma unit.
- What
- EU approval for Dazublys, a trastuzumab biosimilar drug.
- When
- Not specified in articles.
- Where
- Europe
- Why
- Not specified in articles.
- Drug Name
- Dazublys
- Drug Type
- Trastuzumab biosimilar
- Company
- CuraTeQ Biologics (Aurobindo Pharma)
- Target Cancers
- HER2-positive breast and gastric cancers
- Approval Authority
- European Commission
- Stock Movement
- Aurobindo Pharma shares up 2.23%